Interspecies scaling and comparisons in drug development and toxicokinetics

References

• Batra V. K., Yacobi A. An overview of toxicokinetics. Toxicokinetics and New Drug Development, A. Yacobi, J. P. Skelly, V. K. Batra. Pergamon Press. 1989; 1–20
   Google Scholar
• Benowitz N., Forsyth R. P., Melmon K. L., Rowland M. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clinical Pharmacology and Therapeutics 1974; 16: 87–98
   PubMed Web of Science ®Google Scholar
• Benowitz N., Forsyth R. P., Melmon K. L., Rowland M. Lidocaine disposition kinetics in monkey and man. II. Effects of hemorrhage and sympathomimetic drug administration. Clinical Pharmacology and Therapeutics 1974; 16: 99–109
   PubMed Web of Science ®Google Scholar
• Bickis M., Krewski D. Statistical design and analysis of the long-term carcinogenicity bioassay. Toxicologyical Risk Assessment, D. B. Clayson, D. Krewski, I. Munro. CRC Press, Boca Raton, FL 1988; 125–147
   Google Scholar
• Bischoff K. B. Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemotherapy Reports Part I 1975; 59: 777–793
   PubMedGoogle Scholar
• Boddy A., Aarons L., Petrak K. Efficiency of drug targeting in steady-state considerations using a three-compartment model. Pharmaceutical Research 1989; 6: 367–372
   PubMed Web of Science ®Google Scholar
• Bonati M., Latini R., Tognoni G., Youg J. F., Garattini S. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Metabolism Reviews 1985; 15: 1355–1383
   Web of Science ®Google Scholar
• Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 1980; 8: 165–176
   PubMedGoogle Scholar
• Boxenbaum H. Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1982 a; 10: 201–227
   PubMedGoogle Scholar
• Boxenbaum H. Comparative pharmacokinetics of benzodiazepines in dog and man. Journal of Pharmacokinetics and Biopharmaceutics 1982 b; 10: 411–426
   PubMedGoogle Scholar
• Boxenbaum H. Evolutionary biology, animal behaviour, fourth-dimensional space and the raison d'être of drug metabolism and pharmacokinetics,. Drug Metabolism Reviews 1983; 14: 1057–1097
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metabolism Reviews 1984; 15: 1071–1121
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. Time concepts in physics, biology and pharmacokinetics. Journal of Pharmaceutical Sciences 1986; 75: 1053–1062
   PubMed Web of Science ®Google Scholar
• Boxenbaum H., D'Souza R. Interspecies pharmacokinetic scaling in reductionist and allometric paradigms,. Topics in Pharmaceutical Sciences, D. D. Breimer, P. Speiser. Elsevier Science Publisher B.V., Amsterdam 1987a; 59–61
   Google Scholar
• Boxenbaum H., D'Souza R. Physiological models, allometry, neoteny, space-time and pharmacokinetics,. Pharmacokinetics: Mathematical and Statistical Approaches to Metabolism and Distribution of Chemicals and Drugs, A. Pecile, A. Rescigno. Plenum Press, New York 1987b; 191–214
   Google Scholar
• Boxenbaum H., Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. American Journal of Physiology 1983; 245: R768–R775
   PubMed Web of Science ®Google Scholar
• Boxenbaum H., McCullough C. B., Di Carlo F. J. Mortality kinetics in toxicology studies. Drug Metabolism Reveiws 1986; 16: 321–362
   Google Scholar
• Boxenbaum H., Neafsey P. J., Fournier D. J. Hormesis, Gompertz functions and risk assessment. Drug Metabolism Reviews 1988; 19: 195–229
   PubMed Web of Science ®Google Scholar
• Campbell D. B., Ings R. M. J. New approaches to the use of pharmacokinetics in toxicology and drug development. Human Toxicology 1988; 7: 469–479
   PubMedGoogle Scholar
• Chasseaud L. F. Reasons for monitoring test compound kinetics during toxicity studies. Newer Methods in Toxicity Testing: Kinetic Monitoring. Technical Communications, Letchworth 1988; 13–26
   Google Scholar
• Chen C. N., Andrade J. D. Pharmacokinetic model for simultaneous determination of drug levels in organs and tissues. Journal of Pharmaceutical Sciences 1976; 65: 717–718
   PubMed Web of Science ®Google Scholar
• Chen H.-S. G., Gross J. F. Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models. Journal of Pharmacokinetics and Biopharmaceutics 1979; 7: 117–125
   PubMedGoogle Scholar
• Conley B. A., Forrest A., Egorin K. J., Zuhowski E. G., Sinibaldi V., Van Echo D. A. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NMSC 95580). Cancer Research 1989; 49: 3436–3440
   PubMedGoogle Scholar
• Dedrick R. L. Animal scale-up. Journal of Pharmacokinetics and Biopharmaceutics 1973; 1: 435–461
   PubMedGoogle Scholar
• Dedrick R. L. Interspecies scaling of regional drug delivery. Journal of Pharmaceutical Sciences 1986; 75: 1047–1052
   PubMed Web of Science ®Google Scholar
• Dedrick R. L. Arterial drug infusion: pharmacokinetic problems and pitfalls. Journal of the National Cancer Institute 1988; 80: 84–89
   PubMedGoogle Scholar
• Dedrick R. L., Bischoff K. B., Zaharko D. Z. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemotherapy Reports Part 1 1970; 54: 95–101
   PubMedGoogle Scholar
• De la Inglesia F. A., Greaves P. Role of toxicokinetics in drug safety evaluations. Toxicokinetics and New Drug Development, A. Yacobi, J. P. Skelly, V. K. Batra. Pergamon Press, New York 1989; 21–32
   Google Scholar
• Di Carlo F. J. Metabolism, pharmacokinetics and toxicokinetics defined. Drug Metabolism Reviews 1982; 13: 1–4
   PubMed Web of Science ®Google Scholar
• Egorin M. J., Van Echo D. A., Whitacre M. Y., Forrest A., Sigman L. M., Engisch K. L., Aisner J. Human pharmacokinetics, excretion and metabolism of the anthracycline antibiotic Menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Research 1986; 46: 1513–1520
   PubMed Web of Science ®Google Scholar
• Egorin M. J., Conley B. A., Forrest A., Zuhowski E. G., Sinibaldi V., Van Echo D. A. Phase 1 study and pharmacokinetics of Menogaril (NSC 269148) in patients with hepatic dysfunction. Cancer Research 1987 a; 47: 6104–6110
   PubMed Web of Science ®Google Scholar
• Egorin M. J., Sigman L. M., Van Echo D. A., Forrest A., Whitacre M. Y., Aisner J. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Research 1987 b; 47: 617–623
   PubMed Web of Science ®Google Scholar
• Gabelnick H. L., Dedrick R. L., Bourke R. S. In vivo mass transfer of chloride during exchange hemodialysis. Journal of Applied Physiology 1970; 28: 636–640
   PubMedGoogle Scholar
• Gad S., Weil C. S. Statistics and Experimental Design for Toxicologists. Telford Press, Caldwell, NJ 1986
   Google Scholar
• Gould S. J. Ontogeny and Phylogeny. The Belknap Press of Harvard University Press, Cambridge, MA 1977
   Google Scholar
• Harris P. A., Gross J. F. Preliminary pharmacokinetics model for adriamycin (NSC-123127). Cancer Chemotherapy Reports Part 1 1975; 59: 819–825
   PubMedGoogle Scholar
• Harrison L. I., Gibaldi M. Physiologically based pharmacokinetic model for digoxim distribution in dogs and its preliminary application to humans. Journal of Pharmaceutical Sciences 1977; 66: 1679–1683
   PubMedGoogle Scholar
• Himmelstein K. S., Lutz R. J. A review of the applications of physiologically based pharmacokinetic modelling. Journal of Pharmacokinetics and Biopharmaceutics 1979; 7: 127–145
   PubMedGoogle Scholar
• Igari Y., Sugiyama Y., Sawada Y., Iga T., Hanano M. Prediction of diazepam disposition in rat and man by a physiologically based pharmacokinetic model. Journal of Pharmacokinetics and Biopharmaceutics 1983; 11: 577–593
   PubMedGoogle Scholar
• Xenobiotic Metabolism and Disposition: the design of studies on novel compounds, H. P. A. Illing. CRC Press, Boca Raton, FL 1989
   Google Scholar
• La Du B. N., Mandel H. G., Way E. L. Fundamentals of Drug Metabolism and Drug Disposition. Williams & Wilkins, Baltimore, MD 1972
   Google Scholar
• Lin J. H., Sugiyama Y., Awazu S., Hanano M. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. Journal of Pharmacokinetics and Biopharmaceutics 1982; 10: 637–647
   PubMedGoogle Scholar
• Mordenti J. Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrobial Agents and Chemotherapy Journal 1985 a; 27: 887–891
   PubMedGoogle Scholar
• Mordenti J. Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. Journal of Pharmaceutical Sciences 1985 b; 74: 1097–1099
   PubMed Web of Science ®Google Scholar
• Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. Journal of Pharmaceutical Sciences 1986; 75: 1028–1040
   PubMed Web of Science ®Google Scholar
• Mordenti J., Chappell W. The use of interspecies scaling in toxicokinetics. Toxicokinetics and New Drug Development, A. Yacobi, J. P. Skelly, V. K. Batra. Pergamon Press, New York 1989; 42–96
   Google Scholar
• Parke D. V. The Biochemistry of Foreign Compounds. Pergamon Press, Oxford 1968
   Google Scholar
• Parke D. V., Smith R. L. Drug Metabolism—from microbe to man. Taylor & Francis, London 1977
   Google Scholar
• Prentis R. A., Yvonne L., Walker S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). British Journal of Clinical Pharmacology 1988; 25: 387–396
   PubMed Web of Science ®Google Scholar
• Ramsey J. C. Nonlinear pharmacokinetics relative to toxicity and use of toxicological data. Drug Metabolism Reviews 1982; 13: 779–797
   PubMed Web of Science ®Google Scholar
• Rowland M. Physiologic pharmacokinetic models. Pharmacokinetics: Theory and Methodology, M. Rowland, G. Tucker. Pergamon Press, Oxford 1986; 69–88
   Google Scholar
• Sacher G. A. Relationship of lifespan to brain weight and body weight in mammals. Ciba Foundation Colloquium on Aging 1959; 5: 115–133
   Google Scholar
• Sawada Y., Hanano M., Sugiyama Y., Iga T. Prediction of the disposition of β-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmaceutics 1984 a; 12: 241–261
   PubMedGoogle Scholar
• Sawada Y., Hanano M., Sugiyama Y., Harashima H., Iga T. Prediction of the volumes of distribution of basic drugs in humans based on data from animals. Journal of Pharmacokinetics and Biopharmaceutics 1984 b; 12: 587–596
   PubMedGoogle Scholar
• Stahl W. R. The analysis of biological similarity. Advances in Biological Medical Physics 1963; 9: 355–464
   PubMedGoogle Scholar
• Sugita O., Sawada Y., Sugiyama Y., Iga T., Hanano M. Physiologically based pharmacokinetics of drug-drug interaction: a study of tolbutamide-sulfonamide interaction in rats. Journal of Pharmacokinetics and Biopharmaceutics 1982; 10: 297–316
   PubMedGoogle Scholar
• Swabb E. A., Bonner D. P. Prediction of aztreonam pharmacokinetics in humans based on data from animals. Journal of Pharmacokinetics and Biopharmaceutics 1983; 11: 215–223
   PubMedGoogle Scholar
• Testa B., Jenner P. Drug Metabolism: chemical and biochemical aspects. Marcel Dekker, New York 1976
   Google Scholar
• Williams R. T. Detoxification Mechanisms. Chapman & Hall, London 1959
   Google Scholar
• Yacobi A., Skelly J. P., Batra V. K. Toxicokinetics and New Drug Development. Pergamon Press, New York 1989
   Google Scholar
• Yates E., Kugler P. N. Similarity principles and intrinsic geometries: contrasting approaches to interspecies scaling. Journal of Pharmaceutical Sciences 1986; 75: 1019–1027
   PubMed Web of Science ®Google Scholar